Pharmaceuticals - Indian - Bulk Drugs
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 713.72 | 526.97 | 525.07 | 566.63 | 417.06 |
Total Expenses | 647.62 | 521.62 | 456.57 | 475.51 | 366.30 |
Profit Before Tax | 66.11 | 5.35 | 68.50 | 91.12 | 50.76 |
Profit After Tax | 49.20 | 3.88 | 67.88 | 60.96 | 32.69 |
Operating Profit after Depreciation | 89.56 | 27.26 | 87.37 | 102.28 | 62.97 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 437.26 | 412.02 | 437.99 | 457.36 | 280.49 |
Total Non Current Assets | 500.20 | 468.96 | 482.45 | 502.88 | 389.13 |
Total Current Assets | 533.89 | 410.65 | 377.05 | 309.33 | 218.78 |
TOTAL ASSETS | 1,034.09 | 879.61 | 859.50 | 812.21 | 607.91 |
Total Shareholder's Fund | 536.33 | 460.53 | 470.29 | 410.53 | 348.24 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 50.12 | 22.45 | 45.06 | 90.45 | 39.71 |
Net Cash used in Investing Activities | -52.07 | -29.76 | -27.15 | -151.59 | -42.56 |
Net Cash used in Financing Activities | 30.68 | -31.97 | -11.75 | 92.02 | -2.40 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 713.72 | 526.97 | 525.07 | 566.63 | 417.06 |
Total Expenses | 647.39 | 521.42 | 456.42 | 475.51 | 366.30 |
Profit Before Tax | 66.33 | 5.55 | 68.65 | 91.12 | 50.76 |
Profit After Tax | 49.42 | 4.08 | 68.04 | 60.96 | 32.69 |
Operating Profit after Depreciation | 89.79 | 27.46 | 87.53 | 102.28 | 62.97 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 437.26 | 412.02 | 437.99 | 457.36 | 280.49 |
Total Non Current Assets | 534.36 | 503.54 | 505.92 | 520.58 | 408.32 |
Total Current Assets | 533.89 | 410.65 | 377.05 | 309.33 | 218.78 |
TOTAL ASSETS | 1,068.25 | 914.18 | 882.97 | 829.91 | 627.10 |
Total Shareholder's Fund | 570.49 | 495.10 | 493.76 | 428.22 | 367.42 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 50.12 | 22.45 | 45.06 | 90.45 | 39.71 |
Net Cash used in Investing Activities | -52.07 | -29.76 | -27.15 | -151.59 | -42.56 |
Net Cash used in Financing Activities | 30.68 | -31.97 | -11.75 | 92.02 | -2.40 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 196.75 | 164.45 | 245.80 | 161.48 | 166.64 |
Total Expenses | 165.28 | 130.94 | 212.18 | 132.48 | 138.82 |
Profit Before Tax | 19.54 | 21.83 | 21.74 | 16.53 | 15.16 |
Profit After Tax | 13.86 | 16.37 | 16.05 | 12.29 | 12.05 |
Operating Profit after Depreciation | 32.77 | 34.88 | 35.27 | 30.49 | 28.63 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 196.75 | 164.45 | 245.80 | 161.48 | 166.64 |
Total Expenses | 164.89 | 130.99 | 212.31 | 132.60 | 138.82 |
Profit Before Tax | 19.93 | 21.78 | 21.61 | 16.41 | 15.16 |
Profit After Tax | 14.26 | 16.33 | 15.92 | 12.17 | 12.05 |
Operating Profit after Depreciation | 33.16 | 34.83 | 35.14 | 30.37 | 28.63 |
₹0.4/Share
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
SMS Pharmaceuticals Ltd | ₹217.50 | ₹1,841.18 |
Sun Pharmaceuticals Industries Ltd | ₹1,761.80 | ₹4,22,714.84 |
Divis Laboratories Ltd | ₹5,818.40 | ₹1,54,460.24 |
Cipla Ltd | ₹1,427.30 | ₹1,15,270.75 |
Dr Reddys Laboratories Ltd | ₹1,288.45 | ₹1,07,511.36 |
Torrent Pharmaceuticals Ltd | ₹3,157.60 | ₹1,06,862.73 |
02 Nov 2024, 12:49 pm
08 Aug 2024, 02:06 pm
05 Aug 2024, 05:53 pm
30 Jul 2024, 10:50 am
29 May 2024, 04:05 pm